Corrections:

Juan Wang^1,2,4,*, Yue Zhang^1,*, Kai Yin^3,*, Peiqi Xu², Jie Tian², Jie Ma², Xinyu Tian², Yungang Wang², Xinyi Tang², Huaxi Xu² and Shengjun Wang^1,2

¹Department of Laboratory Medicine, The Affiliated People’s Hospital, Jiangsu University, Zhenjiang, China
²Institute of Laboratory Medicine, Jiangsu Key Laboratory of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, China
³Department of General Surgery, The Affiliated Hospital, Jiangsu University, Zhenjiang, China
⁴Department of Laboratory Medicine, Changzhou TCM Hospital, Changzhou, China
^*These authors contributed equally to this work

Published: February 18, 2022

Copyright: © 2022 Wang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: Due to errors during figure assembly, an accidental duplicate image of panel 4 in Figure 1F was inserted in panel 2 of Figure 1F. The corrected Figure 1F, obtained using the original data, is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2017; 8:4814-4825. DOI: https://doi.org/10.18632/oncotarget.13978

Figure 1: IL-17 inhibits apoptosis of MDSCs. MDSCs were isolated from tumor bearing mice and were then treated with different doses of IL-17. (F) Representative apoptosis analysis of MDSCs treated with IL-17 for 24 h by flow cytometry.